Table 1.
Major characteristics of the sporozoite vaccine formulations.
| Vaccine | Company | Target | Source of Peptide Antigens | Adjuvant | Immune Response | Clinical Status |
|---|---|---|---|---|---|---|
| RTS,S/AS01Ε | GlaxoSmithKline Biologicals SA | Inhibition of sporozoite infection | Circumsporozoite protein | AS01 | Protective humoral/cellular | WHO recommended |
| R21 | Serum Institute of India (Pune, India) | Inhibition of sporozoite infection | Circumsporozoite protein | Matrix-M | Protective humoral | Phase III clinical trial |
| PfSPZ | Sanaria Inc. | Killing of infected hepatocytes | Whole sporozoite | None | Protective humoral/cellular | Phase II clinical trial |
|
PfSPZ-CVac (CVac = Chemoprophylaxis Vaccine) |
Sanaria Inc. | Killing of infected hepatocytes | Whole sporozoite | None | Protective humoral/cellular | Phase II clinical trial |